The downgrade from Buy to Neutral suggests that B. Riley Securities sees less upside potential in Intercept Pharma's stock. However, the increase in price target from $15 to $19 indicates that they still see some potential for growth. This mixed signal could lead to uncertainty among investors, potentially leading to short-term price volatility.